Europe SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country (Germany, France, UK, Italy, Spain, Netherland

Europe SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country (Germany, France, UK, Italy, Spain, Netherlands, Russia, and Rest of Europe) – Market Forecast, 2024–2032

The Europe SGLT2 inhibitors market size is expected to reach USD 7,629.79 million by 2032, according to a new study by Polaris Market Research. The report “Europe SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD) Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country; Market Forecast, 2024–2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

SGLT2 inhibitors are known for their ability to lower blood glucose levels by inhibiting the reabsorption of glucose in the kidneys, leading to its excretion in the urine. This mechanism aids in managing blood sugar levels and contributes to weight loss as the excreted glucose represents a loss of calories. Additionally, SGLT2 inhibitors have demonstrated the ability to reduce cardiovascular risks, which is particularly significant for diabetes patients who are at a higher risk for heart disease. These benefits of SGLT2 inhibitors make them an appealing treatment option for patients and healthcare providers, making them preferable over other diabetes medications.

European governments are pivotal in supporting diabetes care through policies and initiatives such as promoting early diagnosis through regular screenings, encouraging preventive measures such as lifestyle modifications, and subsidizing medication access to enhance affordability and accessibility for the population. Such government support ensures that a larger segment of the population can benefit from advanced treatments such as SGLT2 inhibitors.

The well-established healthcare systems in Europe play a significant role in driving the growth of the SGLT2 inhibitors market in the region. The robust healthcare infrastructure in the region ensures that patients have access to advanced medical treatments and technologies, facilitating widespread adoption and distribution of medications, including SGLT2 inhibitors.

Europe is witnessing rising public health campaigns and education initiatives to raise awareness about diabetes, its complications, and the importance of early diagnosis and management. These initiatives educate the public about the benefits of effective diabetes treatments, including SGLT2 inhibitors, thereby encouraging more people to seek timely medical advice and treatment. The heightened awareness has led to a significant increase in the diagnosis of diabetes and the subsequent use of SGLT2 inhibitors, thereby boosting their market share.

Europe SGLT2 Inhibitors Market Report Highlights

• In terms of drug, the Jardiance (Empagliflozin) segment accounted for the largest revenue share in the Europe SGLT2 inhibitors market in 2023. Major health organizations and regulatory bodies such as the European Medicines Agency (EMA) and the American Diabetes Association (ADA) recommend the use of Jardiance for the treatment of type 2 diabetes.
• The type 2 diabetes segment, by indication, is expected to register the highest CAGR during the forecast period. Governments and healthcare organizations in Europe are implementing policies and initiatives such as promoting early diagnosis through regular screenings, funding diabetes education programs, and subsidizing the cost of medications. Such measures increase accessibility and affordability of diabetes treatments, boosting market growth.
• In 2023, the UK accounted for the largest share of the Europe SGLT2 inhibitors market. The country hosts numerous prominent pharmaceutical companies and research institutions committed to advancing and commercializing treatments for diabetes.
• AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; and Pfizer Inc. are among the key players in Europe.

Polaris Market Research has segmented the Europe SGLT2 inhibitors market report on the basis of indication, drug, distribution channel, and country:

By Indication Outlook (Revenue – USD million, 2019–2032)

• Cardiovascular
• Chronic Kidney Disease (CKD)
• Type 2 Diabetes
• Others

By Drug Outlook (Revenue – USD million, 2019–2032)

• Farxiga (Dapagliflozin)
• Inpefa (Sotagliflozin)
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Qtern (Dapagliflozin/Saxagliptin)
• Other Europe SGLT2 Inhibitors

By Distribution Channel Outlook (Revenue – USD million, 2019–2032)

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Country Outlook (Revenue – USD million, 2019–2032)

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe